Catch up on the top radiology content of the past week.
News|Slideshows|February 22, 2026
Radiology Roundup of New FDA Clearances and Approvals: February 15 — February 21
Author(s)Diagnostic Imaging Staff
Catch up on a variety of new FDA clearances and approvals in radiology from the past week.
Advertisement
From new 3T and 1.5T MRI devices to new preset features for a point-of-care ultrasound system and an expanded approval for a MRI contrast agent, here are key FDA clearances and approvals in radiology from the past week.
Advertisement
Related to this article
Catch up on the top AI-related news and research in radiology over the past month.
Catch up on the most-well viewed radiology content in August 2026.
This summer's breast imaging research spanned digital breast tomosynthesis (DBT) efficiency gains, AI models that flag cancer risk years before diagnosis, a cautionary study on automation bias, and advances in ultrasound, MRI, and contrast-enhanced mammography (CEM). Here is a look back at the most well-viewed breast imaging content of the summer.
Catch up on the top radiology content of the past week.
In a recent interview, Stamatia Destounis, MD, FACR, shared her perspective on recent changes to the BI-RADS system, offering insights on contrast-enhanced mammography, reporting changes for breast MRI and ultrasound, and the importance of auditing for BI-RADS category 3 assessments.
Catch up on the top radiology content of the past week.
Offering ease of integration into existing radiology workflows, the AI-enabled Heartvue.Proton software emphasizes time savings with automation of common measurements for cardiac MRI.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Brain MRI Study Reveals Higher Brain Age Gap and White Matter Hyperintensity for Those in Disadvantaged Neighborhoods
2
The Reading Room Podcast: Assessing the Current Landscape of AI and Reimbursement in Radiology, Part 2
3
Breast Imaging in Focus: Key Pearls from New Guidelines on Proliferative Breast Lesions with Atypia and LCIS
4
Molecular Imaging in Focus: Can the Newly FDA-Approved PET Agent Floretyrosine F18 Have an Impact for Glioma Imaging?
5